Milan - Delayed Quote EUR

Edwards Lifesciences Corporation (1EW.MI)

66.62

+0.57

+(0.86%)

At close: April 7 at 2:24:16 PM GMT+2

Edwards Shoots Higher As It Shrugs Off Tariffs Worries — Until 2026

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Investor's Business Daily yesterday

EW
Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings

Edwards Lifesciences (NYSE:EW) recently announced its updated guidance, projecting second-quarter 2025 sales between $1.45 billion and $1.53 billion, alongside first-quarter results showing a rise in sales and net income compared to the previous year. This aligns with a broader market trend where the S&P 500 and Nasdaq Composite surged, driven by positive earnings reports and easing concerns over tariffs. The company's 2.2% price move over the last quarter reflects the general optimism but...

Simply Wall St. yesterday

EW
Edwards Lifesciences Reports First Quarter Results

IRVINE, Calif., April 23, 2025--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025.

Business Wire 2 days ago

EW
Edwards says eight-year data confirm long-term durability of Resilia tissue

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary Resilia tissue technology have significantly improved long-term outcomes compared to those receiving non-Resilia tissue bioprosthetic valves. Presented at the Heart Valve Society Annual Meeting, the study of 947 patients marks the first long-term, propensity-matched comparison between Resilia tissue and non-Resilia tissue surgical aortic valves. The Resilia

TipRanks 6 days ago

EW
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue

CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves.

Business Wire 7 days ago

EW
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

IRVINE, Calif., April 16, 2025--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Business Wire 9 days ago

EW
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

IRVINE, Calif., April 14, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3 system is the world's first approved transcatheter valve replacement therap

Business Wire 11 days ago

EW
Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session

Edwards Lifesciences (NYSE:EW) recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This development, alongside data indicating the increased effectiveness of electronic notifications in treating severe aortic stenosis, comes amid broader market volatility. The past week saw a 1.58% rise in Edwards Lifesciences' stock, contrasting with a 3.4% drop in the overall market as concerns about tariffs...

Simply Wall St. 24 days ago

EW
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients

CHICAGO, March 31, 2025--Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease.

Business Wire 25 days ago

EW
Edwards Lifesciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Edwards Lifesciences ( NYSE:EW ) Full Year 2024 Results Key Financial Results Revenue: US$5.44b (up 8.6% from FY 2023...

Simply Wall St. last month

EW
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference

IRVINE, Calif., February 25, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.

Business Wire last month

EW
The three-year loss for Edwards Lifesciences (NYSE:EW) shareholders likely driven by its shrinking earnings

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. 2 months ago

EW
Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Investor's Business Daily 2 months ago

EW
Edwards Lifesciences (NYSE:EW) Is Reinvesting At Lower Rates Of Return

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...

Simply Wall St. 2 months ago

EW
Edwards Lifesciences Reports Fourth Quarter Results

IRVINE, Calif., February 11, 2025--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

Business Wire 2 months ago

EW
Edwards Lifesciences Corporation (NYSE:EW) is a favorite amongst institutional investors who own 88%

Key Insights Given the large stake in the stock by institutions, Edwards Lifesciences' stock price might be vulnerable...

Simply Wall St. 2 months ago

EW
Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025

IRVINE, Calif., February 04, 2025--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Business Wire 2 months ago

EW
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Edwards Lifesciences fair value estimate is US$68.71 Edwards...

Simply Wall St. 2 months ago

EW
What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing?

Let's talk about the popular Edwards Lifesciences Corporation ( NYSE:EW ). The company's shares saw significant share...

Simply Wall St. 2 months ago

EW
Declining Stock and Solid Fundamentals: Is The Market Wrong About Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) has had a rough week with its share price down 5.2%. However, a closer look at its sound...

Simply Wall St. 3 months ago

EW

Performance Overview

Return	1EW.MI	S&P 500 (^GSPC)
YTD	-7.40%	-6.06%
1-Year	-21.48%	+9.44%
3-Year	-4.31%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Edwards Lifesciences Corporation (1EW.MI)

Edwards Shoots Higher As It Shrugs Off Tariffs Worries — Until 2026

Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings

Edwards Lifesciences Reports First Quarter Results

Edwards says eight-year data confirm long-term durability of Resilia tissue

Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session

New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients

Edwards Lifesciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference

The three-year loss for Edwards Lifesciences (NYSE:EW) shareholders likely driven by its shrinking earnings

Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion

Edwards Lifesciences (NYSE:EW) Is Reinvesting At Lower Rates Of Return

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences Corporation (NYSE:EW) is a favorite amongst institutional investors who own 88%

Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing?

Declining Stock and Solid Fundamentals: Is The Market Wrong About Edwards Lifesciences Corporation (NYSE:EW)?

Performance Overview